Featured Research

from universities, journals, and other organizations

Study estimates potential for ranibizumab to prevent blindness from age-related macular degeneration

Date:
June 15, 2011
Source:
JAMA and Archives Journals
Summary:
A computer modeling study suggests that administering the drug ranibizumab is associated with reducing the magnitude of legal blindness and visual impairment caused by age-related macular degeneration in non-Hispanic white individuals, according to a new study.

A computer modeling study suggests that administering the drug ranibizumab is associated with reducing the magnitude of legal blindness and visual impairment caused by age-related macular degeneration in non-Hispanic white individuals, according to a report in the June issue of Archives of Ophthalmology, one of the JAMA/Archives journals.

"Before ranibizumab became available in 2006, neovascular age-related macular degeneration (AMD) was reported to be the leading cause of blindness in individuals 50 years and older in the United States and throughout many parts of the world," the authors write as background information in the article.

To estimate the number of individuals in the United States who may benefit from treatment with ranibizumab to treat neovascular AMD (occurs when new blood vessels form in the retinal tissue, that can break easily, causing bleeding and damage to surrounding tissue) and prevent AMD-related blindness, Neil M. Bressler, M.D., of Wilmer Eye Institute, The Johns Hopkins University, Baltimore, and colleagues designed a modeling study using outcomes from three previous phase 3 ranibizumab trials.

Using statistics from the Beaver Dam Eye Study and data from the 2008 U.S. Census Bureau, the model predicted that 151,340 non-Hispanic white individuals in 2008 would develop neovascular AMD. Using data from the Age-Related Eye Disease Study (a phase 3 ranibizumab trial), the authors estimated that one-third of these cases (51,000 individuals) would already have preexisting choroidal neovascularization (new blood vessels form in the choroid, a thin vascular layer that supplies blood to the retina) in the opposite eye, making those patients ineligible for the model used in this study. Of the 151,340 individuals, the authors estimated that ranibizumab would be accessible to 103,582 individuals, making them eligible for inclusion in the study's modeling criteria.

Based on the model designed for the study, if no treatment were given to the 103,582 cases for which monthly ranibizumab was indicated and accessible, 16,268 (16 percent) would progress to legal blindness in two years. The authors estimated that monthly ranibizumab usage would reduce the incidence of legal blindness in two years by 72 percent, to 4,484 individuals. Additionally, based on the model designed for the study, if no treatment were applied to the 103,582 cases for which monthly ranibizumab is indicated and accessible, 34,702 (34 percent) would progress in two years to visual impairment (worse than 20/40 in the better-seeing eye, a level that precludes an unrestricted driver's license in most states). The authors estimated that monthly ranibizumab usage would reduce the incidence of visual impairment in two years by 37 percent, to 21,919 individuals.

Based on results of the model designed for this study, the authors conclude that ranibizumab would have an effect on reducing the occurrence of visual blindness in individuals with AMD when treatment is administered on a monthly basis when available.


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Journal Reference:

  1. Neil M. Bressler; Quan V. Doan; Rohit Varma; Paul P. Lee; Ivan J. Suner; Chantal Dolan; Mark D. Danese; Elaine Yu; Irwin Tran; Shoshana Colman. Estimated Cases of Legal Blindness and Visual Impairment Avoided Using Ranibizumab for Choroidal Neovascularization: Non-Hispanic White Population in the United States With Age-Related Macular Degeneration. Archives of Ophthalmology, 2011; 129 (6): 709-717 DOI: 10.1001/archophthalmol.2011.140

Cite This Page:

JAMA and Archives Journals. "Study estimates potential for ranibizumab to prevent blindness from age-related macular degeneration." ScienceDaily. ScienceDaily, 15 June 2011. <www.sciencedaily.com/releases/2011/06/110613162101.htm>.
JAMA and Archives Journals. (2011, June 15). Study estimates potential for ranibizumab to prevent blindness from age-related macular degeneration. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2011/06/110613162101.htm
JAMA and Archives Journals. "Study estimates potential for ranibizumab to prevent blindness from age-related macular degeneration." ScienceDaily. www.sciencedaily.com/releases/2011/06/110613162101.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Xtreme Eating: Your Daily Caloric Intake All On One Plate

Xtreme Eating: Your Daily Caloric Intake All On One Plate

Newsy (July 30, 2014) The Center for Science in the Public Interest released its 2014 list of single meals with whopping calorie counts. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



    Save/Print:
    Share:

    Free Subscriptions


    Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

    Get Social & Mobile


    Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

    Have Feedback?


    Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
    Mobile: iPhone Android Web
    Follow: Facebook Twitter Google+
    Subscribe: RSS Feeds Email Newsletters
    Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins